42. The composition of claim **35** further comprising a buffer selected from a group consisting of histidine buffer, citrate buffer, alginate buffer, and arginine buffer.

43. The composition of claim **35** further comprising a tonicity modifier.

44. The composition of claim **35**, wherein concentration of the protein of interest is about 20 mg/mL to about 400 mg/mL.

45. A composition having a protein of interest purified from mammalian cells, surfactant and a residual amount of liver carboxylesterase 1-like protein, wherein the residual amount of lysosomal acid lipase is less than about 5 ppm.

46. The composition of claim **45**, wherein the surfactant is polysorbate.

47. The composition of claim **46**, wherein the surfactant is polysorbate 80.

48. The composition of claim **47**, wherein the liver carboxylesterase 1-like protein causes degradation of the polysorbate 80.

49. The composition of claim **46**, wherein the composition is a parenteral formulation

50. The composition of claim **46**, wherein concentration of the polysorbate in the composition is about 0.01% w/v to about 0.2% w/v.

51. The composition of claim **45**, wherein the protein of interest is selected from a group consisting of a monoclonal antibody, a polyclonal antibody, a bispecific antibody, an antibody fragment and antibody-drug complex.

52. The composition of claim **45** further comprising one or more pharmaceutically acceptable excipients.

53. The composition of claim **45** further comprising a buffer selected from a group consisting of histidine buffer, citrate buffer, alginate buffer, and arginine buffer.

54. The composition of claim **45** further comprising a tonicity modifier.

55. The composition of claim **45**, wherein concentration of the protein of interest is about 20 mg/mL to about 400 mg/mL.

* * * * *